A Phase 1b, Open-Label, Multicenter Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Preliminary Clinical Activity of CND261 in Patients with Seropositive Rheumatoid Arthritis
This research is looking into a new medication called CND261 for adults living with a specific type of rheumatoid arthritis. This is an "early-stage" study, which means it's one of the first times this new medicine is being tested in humans. The main goals are to check if CND261 is safe to use and how well people can tolerate it. Researchers will also be looking at how the body processes the medicine and how it might affect the illness. They will also be checking for any unwanted reactions from the body's immune system. While the main focus is safety, the study will also gather early information on whether the medicine shows any signs of reducing symptoms of rheumatoid arthritis. If you have seropositive rheumatoid arthritis, this study might be an option for you if you fit the other requirements.
At a glance
What is this study about?
This study is about a new medicine called CND261. It's designed for people who have a condition called seropositive rheumatoid arthritis. Rheumatoid arthritis is a long-lasting illness where your body's immune system mistakenly attacks your joints, causing pain, swelling, and stiffness. "Seropositive" means that certain markers linked to this condition are found in your blood.
The main purpose of this study is to carefully examine this new medicine. Researchers want to find out if it's safe for people to take and if there are any side effects. They also want to understand how the medicine moves through your body, how long it stays, and how it might affect your body's processes. Because it's a new medicine, they will also look at how your immune system reacts to it.
This is an early phase of testing (sometimes called Phase 1b). This means that while safety is the top priority, the doctors will also be gently looking for any early signs that the medicine could help improve the symptoms of rheumatoid arthritis. Finding new ways to manage rheumatoid arthritis is very important, and studies like this help us understand if new treatments could be helpful in the future.
Key takeaways
- This study is testing a new medicine, CND261, for seropositive rheumatoid arthritis.
- It's an early-stage study, so checking safety is the main goal.
- Researchers will also see how the body handles the medicine and if it shows early signs of helping symptoms.
- You must be an adult (18+) with seropositive rheumatoid arthritis to be considered.
- Participation involves regular clinic visits, tests, and taking the study medicine.
- You can stop participating at any time if you wish.
Who may be eligible?
To join this study, there are certain requirements you need to meet. The study is open to adults aged 18 years and older; there is no upper age limit. It’s open to both men and women.
Crucially, you must have been diagnosed with "seropositive rheumatoid arthritis." This isn't just any type of arthritis; it's a specific kind where doctors have found particular indicators in your blood tests confirming this diagnosis.
There might be other health conditions or medicines you are currently taking that would mean this study isn't right for you. These are usually in place to make sure that the study is as safe as possible for everyone involved and that the results are clear. Your doctor or the study team will be able to go through all these details with you.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Am I 18 years old or older?
- Do I have a diagnosis of 'seropositive rheumatoid arthritis'?
- Am I willing to attend regular clinic visits?
- Am I willing to take a new, experimental medicine?
- Am I comfortable with regular blood tests and other assessments?
What does participation involve?
If you decide to join this study, it will involve several steps over a period of time. You would have regular visits to the clinic where you would meet the study doctors and nurses. During these visits, they would perform various checks, which might include:
* **Physical exams:** To assess your general health. * **Blood tests:** To check how your body is reacting to the medicine and to monitor your general health. * **Urine samples:** For similar checks. * **Taking the study medicine:** You would be given the CND261 medicine as instructed by the study team. * **Filling out questionnaires:** To describe your symptoms and how you're feeling.
The study involves taking a new medicine, and you would be closely monitored throughout. After you finish taking the medicine, there will likely be follow-up visits to ensure your well-being and to continue gathering information. The total duration of your participation would be explained to you in full before you agree to join.
Potential risks and benefits
Locations (1)
- —UnverifiedRomania
Common questions
What is 'seropositive rheumatoid arthritis'?
It's a type of rheumatoid arthritis where doctors find certain markers in your blood, which helps confirm the diagnosis.
Why is this called an 'early-stage' study?
It means this is one of the first times this new medicine, CND261, is being tested in people. The main goal is to check its safety.
Will this medicine cure my rheumatoid arthritis?
It's too early to say. This study is mainly about checking safety. Any positive effects on symptoms would be preliminary findings at this stage.
What kind of tests will I have if I join?
You'll likely have regular physical exams, blood tests, and possibly urine tests, along with taking the study medicine.
Can I stop participating if I change my mind?
Yes, you can leave the study at any time, for any reason, without it affecting your medical care.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.